Strong Dollar, Weak Performance: Big Pharma Is An Industry Adrift
This article was originally published in Scrip
On the face of it, the latest quarterly results from the 10 biggest drug companies indicate that eight of them will have lower drug sales in 2015 than in 2014. The mood music behind the Q3 numbers is wistful and selective, suggesting that some of the biggest names in the industry are not sure where they are going even though they know that they don't really want to start from here.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.